Iterum Therapeutics
Yahoo Finance • 29 days ago
Iterum Therapeutics Provides Business Update
DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi... Full story
Yahoo Finance • last month
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading
(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipation. Here are the highlights from Novembe... Full story
Yahoo Finance • 2 months ago
Iterum projects $5M–$15M in 2026 ORLYNVAH sales while advancing streamlined commercialization and payer access
Earnings Call Insights: Iterum Therapeutics (ITRM) Q3 2025 MANAGEMENT VIEW * Corey Fishman, President, CEO & Director, opened by emphasizing the early progress in commercializing ORLYNVAH following its August market launch and highligh... Full story
Yahoo Finance • 2 months ago
Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close
(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates. Shares of Milestone Scientific Inc. (MLSS) rose sharply in extended trading, climbing to $0.52... Full story
Yahoo Finance • 2 months ago
Here are the major earnings before the open Friday
Major earnings expected before the bell on Friday include: * HIVE Digital Technologies Ltd. (HIVE [https://seekingalpha.com/symbol/HIVE]) * Bit Digital (BTBT [https://seekingalpha.com/symbol/BTBT]) * Allianz SE (OTCPK:ALIZY [https:/... Full story
Yahoo Finance • 2 months ago
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant p... Full story
Yahoo Finance • 3 months ago
Iterum Therapeutics to Present Data at IDWeek 2025
DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathog... Full story
Yahoo Finance • 4 months ago
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both co... Full story
Yahoo Finance • 5 months ago
Iterum Therapeutics PLC (NASDAQ:ITRM) Reports Wider Q2 2025 Loss, Market Optimistic Ahead of ORLYNVAH Launch
ITERUM THERAPEUTICS PLC (NASDAQ:ITRM [https://www.chartmill.com/stock/quote/ITRM/profile] REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, MARKET REACTS POSITIVELY AHEAD OF KEY LAUNCH Iterum Therapeutics PLC released its second-quarter... Full story
Yahoo Finance • 5 months ago
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
-- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focu... Full story
Yahoo Finance • 5 months ago
Which stocks are moving after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ADAP [https://www.... Full story
Yahoo Finance • 5 months ago
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant p... Full story
Yahoo Finance • 6 months ago
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-dru... Full story
Yahoo Finance • 6 months ago
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug re... Full story
Yahoo Finance • 7 months ago
Iterum Therapeutics Announces Partnership for Commercialization Services
U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: I... Full story
Yahoo Finance • 8 months ago
Iterum Therapeutics Announces Extension of Term of Promissory Note
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug res... Full story
Yahoo Finance • 9 months ago
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both c... Full story
Yahoo Finance • 11 months ago
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on... Full story
Yahoo Finance • 11 months ago
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant p... Full story
Yahoo Finance • 2 years ago
Iterum Therapeutics Reports Third Quarter 2023 Financial Results
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum... Full story
